Benefits for seven items that have been canceled for not participating in the clinical re-evaluation of the brain function improvement drug Choline alfoscerate will be suspended from the 21st.

The MOHW announced on the 18th that it has decided to suspend health insurance benefits for drugs that have been canceled for product licenses due to confirmation of violations of the Pharmaceutical Affairs Act.

The seven items violating the Pharmaceutical Affairs Act were canceled following the first two-month suspension of sales and the second six-month suspension of sales without complying with Article 33 (Regulations on the Reevaluation of Drugs) under the Choline alfoscerate formulation.